journal
MENU ▼
Read by QxMD icon Read
search

Annals of the Rheumatic Diseases

journal
https://www.readbyqxmd.com/read/28219882/incident-myocardial-infarction-associated-with-major-types-of-arthritis-in-the-general-population-a-systematic-review-and-meta-analysis
#1
Orit Schieir, Cedomir Tosevski, Richard H Glazier, Sheilah Hogg-Johnson, Elizabeth M Badley
OBJECTIVE: To synthesise, quantify and compare risks for incident myocardial infarction (MI) across five major types of arthritis in population-based studies. METHODS: A systematic search was performed in MEDLINE, EMBASE and CINAHL databases with additional manual/hand searches for population-based cohort or case-control studies published in English of French between January 1980 and January 2015 with a measure of effect and variance for associations between incident MI and five major types of arthritis: rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), gout or osteoarthritis (OA), adjusted for at least age and sex...
February 20, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28213566/a-randomised-phase-iib-study-of-mavrilimumab-a-novel-gm-csf-receptor-alpha-monoclonal-antibody-in-the-treatment-of-rheumatoid-arthritis
#2
Gerd R Burmester, Iain B McInnes, Joel Kremer, Pedro Miranda, Mariusz Korkosz, Jiri Vencovsky, Andrea Rubbert-Roth, Eduardo Mysler, Matthew A Sleeman, Alex Godwood, Dominic Sinibaldi, Xiang Guo, Wendy I White, Bing Wang, Chi-Yuan Wu, Patricia C Ryan, David Close, Michael E Weinblatt
OBJECTIVES: Despite the therapeutic value of current rheumatoid arthritis (RA) treatments, agents with alternative modes of action are required. Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, was evaluated in patients with moderate-to-severe RA. METHODS: In a phase IIb study (NCT01706926), patients with inadequate response to ≥1 synthetic disease-modifying antirheumatic drug(s), Disease Activity Score 28 (DAS28)-C reactive protein (CRP)/erythrocyte sedimentation rate ≥3...
February 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28213565/anti-tnf-induced-remission-in-very-early-peripheral-spondyloarthritis-the-crespa-study
#3
Philippe Carron, Gaëlle Varkas, Heleen Cypers, Liesbet Van Praet, Dirk Elewaut, Filip Van den Bosch
OBJECTIVE: To evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA). METHODS: Clinical REmission in peripheral SPondyloArthritis is a monocentric study of golimumab treatment in patients with pSpA. All patients fulfilled the Assessment of SpondyloArthritis international Society classification criteria for pSpA, with a symptom duration ≤12 weeks. Patients were randomised 2:1 to receive golimumab 50 mg every 4 weeks or matching placebo for 24 weeks...
February 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28213564/seven-year-tolerability-profile-of-glucocorticoids-use-in-early-rheumatoid-arthritis-data-from-the-espoir-cohort
#4
Camille Roubille, Nathalie Rincheval, Maxime Dougados, René-Marc Flipo, Jean-Pierre Daurès, Bernard Combe
OBJECTIVE: To explore the 7-year tolerability profile of glucocorticoids (GC) for early rheumatoid arthritis (RA). METHODS: We examined data for 602 patients with RA from the early arthritis Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort (<6 months disease duration) stratified into two groups: with or without GC treatment at least once during follow-up (median 7 years (IQR 0.038-7.65)). The main outcome was a composite of death, cardiovascular disease (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection and fracture...
February 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28213563/development-and-validation-of-a-patient-reported-outcome-instrument-for-skin-involvement-in-patients-with-systemic-sclerosis
#5
Ada Man, Jeannette K Correa, Jessica Ziemek, Robert W Simms, David T Felson, Robert Lafyatis
OBJECTIVES: We developed a patient-reported outcome (PRO) instrument to assess the skin-related quality of life in patients with systemic sclerosis (SSc). METHODS: Participants with SSc provided input on skin-related health effects through focus groups. We developed items for scleroderma skin PRO (SSPRO) to encompass these effects. Further consideration from cognitive interviews and an expert panel led to reduction and modification of items. A 22-item SSPRO was field tested...
February 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28209630/inhibition-of-phosphodiesterase-4-pde4-reduces-dermal-fibrosis-by-interfering-with-the-release-of-interleukin-6-from-m2-macrophages
#6
Christiane Maier, Andreas Ramming, Christina Bergmann, Rita Weinkam, Nicolai Kittan, Georg Schett, Jörg H W Distler, Christian Beyer
OBJECTIVES: To investigate the disease-modifying effects of phosphodiesterase 4 (PDE4) inhibition in preclinical models of systemic sclerosis (SSc). METHODS: We studied the effects of PDE4 inhibition in a prevention and a treatment model of bleomycin-induced skin fibrosis, in the topoisomerase mouse model as well as in a model of sclerodermatous chronic graft-versus-host disease. To better understand the mode of action of PDE4 blockade in preclinical models of SSc, we investigated fibrosis-relevant mediators in fibroblasts and macrophages from healthy individuals and patients suffering from diffuse-cutaneous SSc on blockade of PDE4...
February 16, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28209629/burden-of-musculoskeletal-disorders-in-the-eastern-mediterranean-region-1990-2013-findings-from-the-global-burden-of-disease-study-2013
#7
Maziar Moradi-Lakeh, Mohammad H Forouzanfar, Stein Emil Vollset, Charbel El Bcheraoui, Farah Daoud, Ashkan Afshin, Raghid Charara, Ibrahim Khalil, Hideki Higashi, Mohamed Magdy Abd El Razek, Aliasghar Ahmad Kiadaliri, Khurshid Alam, Nadia Akseer, Nawal Al-Hamad, Raghib Ali, Mohammad AbdulAziz AlMazroa, Mahmoud A Alomari, Abdullah A Al-Rabeeah, Ubai Alsharif, Khalid A Altirkawi, Suleman Atique, Alaa Badawi, Lope H Barrero, Mohammed Basulaiman, Shahrzad Bazargan-Hejazi, Neeraj Bedi, Isabela M Bensenor, Rachelle Buchbinder, Hadi Danawi, Samath D Dharmaratne, Faiez Zannad, Maryam S Farvid, Seyed-Mohammad Fereshtehnejad, Farshad Farzadfar, Florian Fischer, Rahul Gupta, Randah Ribhi Hamadeh, Samer Hamidi, Masako Horino, Damian G Hoy, Mohamed Hsairi, Abdullatif Husseini, Mehdi Javanbakht, Jost B Jonas, Amir Kasaeian, Ejaz Ahmad Khan, Jagdish Khubchandani, Ann Kristin Knudsen, Jacek A Kopec, Raimundas Lunevicius, Hassan Magdy Abd El Razek, Azeem Majeed, Reza Malekzadeh, Kedar Mate, Alem Mehari, Michele Meltzer, Ziad A Memish, Mojde Mirarefin, Shafiu Mohammed, Aliya Naheed, Carla Makhlouf Obermeyer, In-Hwan Oh, Eun-Kee Park, Emmanuel Kwame Peprah, Farshad Pourmalek, Mostafa Qorbani, Anwar Rafay, Vafa Rahimi-Movaghar, Rahman Shiri, Sajjad Ur Rahman, Rajesh Kumar Rai, Saleem M Rana, Sadaf G Sepanlou, Masood Ali Shaikh, Ivy Shiue, Abla Mehio Sibai, Diego Augusto Santos Silva, Jasvinder A Singh, Jens Christoffer Skogen, Abdullah Sulieman Terkawi, Kingsley N Ukwaja, Ronny Westerman, Naohiro Yonemoto, Seok-Jun Yoon, Mustafa Z Younis, Zoubida Zaidi, Maysaa El Sayed Zaki, Stephen S Lim, Haidong Wang, Theo Vos, Mohsen Naghavi, Alan D Lopez, Christopher J L Murray, Ali H Mokdad
OBJECTIVES: We used findings from the Global Burden of Disease Study 2013 to report the burden of musculoskeletal disorders in the Eastern Mediterranean Region (EMR). METHODS: The burden of musculoskeletal disorders was calculated for the EMR's 22 countries between 1990 and 2013. A systematic analysis was performed on mortality and morbidity data to estimate prevalence, death, years of live lost, years lived with disability and disability-adjusted life years (DALYs)...
February 16, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28196800/challenging-judgement-of-a-low-positive-acpa-test-in-the-context-of-individuals-at-risk-of-ra
#8
LETTER
Aase Haj Hensvold, Anca I Catrina
No abstract text is available yet for this article.
February 14, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28188239/treatment-outcome-in-early-diffuse-cutaneous-systemic-sclerosis-the-european-scleroderma-observational-study-esos
#9
Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, Mark Lunt, Roger Hesselstrand, Luc Mouthon, Alan Silman, Edith Brown, László Czirják, Jörg H W Distler, Oliver Distler, Kim Fligelstone, William J Gregory, Rachel Ochiel, Madelon Vonk, Codrina Ancuţa, Voon H Ong, Dominique Farge, Marie Hudson, Marco Matucci-Cerinic, Alexandra Balbir-Gurman, Øyvind Midtvedt, Alison C Jordan, Paresh Jobanputra, Wendy Stevens, Pia Moinzadeh, Frances C Hall, Christian Agard, Marina E Anderson, Elisabeth Diot, Rajan Madhok, Mohammed Akil, Maya H Buch, Lorinda Chung, Nemanja Damjanov, Harsha Gunawardena, Peter Lanyon, Yasmeen Ahmad, Kuntal Chakravarty, Søren Jacobsen, Alexander J MacGregor, Neil McHugh, Ulf Müller-Ladner, Gabriela Riemekasten, Michael Becker, Janet Roddy, Patricia E Carreira, Anne Laure Fauchais, Eric Hachulla, Jennifer Hamilton, Murat İnanç, John S McLaren, Jacob M van Laar, Sanjay Pathare, Susannah Proudman, Anna Rudin, Joanne Sahhar, Brigitte Coppere, Christine Serratrice, Tom Sheeran, Douglas J Veale, Claire Grange, Georges-Selim Trad, Christopher P Denton
OBJECTIVES: The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches. METHODS: This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening). Clinicians selected one of four protocols for each patient: methotrexate, mycophenolate mofetil (MMF), cyclophosphamide or 'no immunosuppressant'...
February 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28183721/carbamylation-of-vimentin-is-inducible-by-smoking-and-represents-an-independent-autoantigen-in-rheumatoid-arthritis
#10
Caroline Ospelt, Holger Bang, Eugen Feist, Giovanni Camici, Stephan Keller, Jacqueline Detert, Anette Krämer, Steffen Gay, Khetam Ghannam, Gerd R Burmester
OBJECTIVES: Smoking has been connected to citrullination of antigens and formation of anti-citrullinated peptide antibodies (ACPAs) in rheumatoid arthritis (RA). Since smoking can modify proteins by carbamylation (formation of homocitrulline), this study was conducted to investigate these effects on vimentin in animal models and RA. METHODS: The efficiency of enzymatic carbamylation of vimentin was characterised. B-cell response was investigated after immunisation of rabbits with different vimentin isoforms...
February 9, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28183720/response-to-clinical-benefit-of-vedolizumab-on-articular-manifestations-in-patients-with-active-spondyloarthritis-associated-with-inflammatory-bowel-disease-by-orlando-et-al
#11
LETTER
G Varkas, F Van den Bosch, D Elewaut
No abstract text is available yet for this article.
February 9, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28179266/response-to-regulatory-role-of-the-jak-stat-kinase-signalling-system-on-the-il-23-il-17-cytokine-axis-in-psoriatic-arthritis-by-raychaudhuri-et-al
#12
LETTER
Trudy McGarry, Wei Gao, Douglas J Veale, Ursula Fearon
No abstract text is available yet for this article.
February 8, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28179265/regulatory-role-of-the-jak-stat-kinase-signalling-system-on-the-il-23-il-17-cytokine-axis-in-psoriatic-arthritis
#13
LETTER
Smriti K Raychaudhuri, Christine Abria, Siba P Raychaudhuri
No abstract text is available yet for this article.
February 8, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28179264/performance-of-the-asas-classification-criteria-for-axial-and-peripheral-spondyloarthritis-a-systematic-literature-review-and-meta-analysis
#14
Alexandre Sepriano, Roxana Rubio, Sofia Ramiro, Robert Landewé, Désirée van der Heijde
OBJECTIVE: To summarise the evidence on the performance of the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (axSpA) (also imaging and clinical arm separately), peripheral (p)SpA and the entire set, when tested against the rheumatologist's diagnosis ('reference standard'). METHODS: A systematic literature review was performed to identify eligible studies. Raw data on SpA diagnosis and classification were extracted or, if necessary, obtained from the authors of the selected publications...
February 8, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28153830/non-steroidal-anti-inflammatory-drugs-for-spinal-pain-a-systematic-review-and-meta-analysis
#15
Gustavo C Machado, Chris G Maher, Paulo H Ferreira, Richard O Day, Marina B Pinheiro, Manuela L Ferreira
BACKGROUND: While it is now clear that paracetamol is ineffective for spinal pain, there is not consensus on the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) for this condition. We performed a systematic review with meta-analysis to determine the efficacy and safety of NSAIDs for spinal pain. METHODS: We searched MEDLINE, EMBASE, CINAHL, CENTRAL and LILACS for randomised controlled trials comparing the efficacy and safety of NSAIDs with placebo for spinal pain...
February 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28153829/pharmacological-inhibition-of-porcupine-induces-regression-of-experimental-skin-fibrosis-by-targeting-wnt-signalling
#16
Chih-Wei Chen, Christian Beyer, Jun Liu, Christiane Maier, Chun Li, Thuong Trinh-Minh, Xiaohan Xu, Stuart H Cole, Mindy H Hsieh, Nicholas Ng, Alana Althage, Shelly Meeusen, Shifeng Pan, Eric C Svensson, H Martin Seidel, Georg Schett, Peter Gergely, Jennifer L Harris, Jörg H W Distler
OBJECTIVES: Wnt signalling has been implicated in activating a fibrogenic programme in fibroblasts in systemic sclerosis (SSc). Porcupine is an O-acyltransferase required for secretion of Wnt proteins in mammals. Here, we aimed to evaluate the antifibrotic effects of pharmacological inhibition of porcupine in preclinical models of SSc. METHODS: The porcupine inhibitor GNF6231 was evaluated in the mouse models of bleomycin-induced skin fibrosis, in tight-skin-1 mice, in murine sclerodermatous chronic-graft-versus-host disease (cGvHD) and in fibrosis induced by a constitutively active transforming growth factor-β-receptor I...
February 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28153828/clinical-benefit-of-1-year-certolizumab-pegol-czp-add-on-therapy-to-methotrexate-treatment-in-patients-with-early-rheumatoid-arthritis-was-observed-following-czp-discontinuation-2-year-results-of-the-c-opera-study-a-phase-iii-randomised-trial
#17
Tatsuya Atsumi, Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Shinsuke Yasuda, Yuji Yamanishi, Yasuhiko Kita, Tsukasa Matsubara, Masahiro Iwamoto, Toshiharu Shoji, Osamu Togo, Toshiyuki Okada, Désirée van der Heijde, Nobuyuki Miyasaka, Takao Koike
OBJECTIVES: To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. METHODS: MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were eligible to enter Certolizumab-Optimal Prevention of joint damage for Early RA (C-OPERA), a multicentre, randomised, controlled study, which consisted of a 52-week double-blind (DB) period and subsequent 52-week post treatment (PT) period...
February 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28143815/long-term-safety-of-tofacitinib-for-the-treatment-of-rheumatoid-arthritis-up-to-8-5%C3%A2-years-integrated-analysis-of-data-from-the-global-clinical-trials
#18
Stanley B Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R Curtis, Eun Bong Lee, Peter Nash, Kevin L Winthrop, Christina Charles-Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi, Jamie Geier, Kenneth Kwok, Lisy Wang, Richard Riese, Jürgen Wollenhaupt
OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pooled for all tofacitinib-treated patients (data cut-off: 31 March 2015). Incidence rates (IRs; patients with event/100 patient-years) and 95% CIs are reported for adverse events (AEs) of interest...
January 31, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28137916/optical-coherence-tomography-as-a-method-for-quantitative-skin-evaluation-in-systemic-sclerosis
#19
LETTER
Natália Sotero Machado Pires, Andréa Tavares Dantas, Angela Luzia Branco Pinto Duarte, Marcello Magri Amaral, Luana Osório Fernandes, Tereza Januária Costa Dias, Luciana Santos Afonso de Melo, Anderson Stevens Leônidas Gomes
No abstract text is available yet for this article.
January 30, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28137915/societal-costs-and-patients-experience-of-health-inequities-before-and-after-diagnosis-of-psoriatic-arthritis-a-danish-cohort-study
#20
Lars Erik Kristensen, Tanja S Jørgensen, Robin Christensen, Henrik Gudbergsen, Lene Dreyer, Christine Ballegaard, Lennart T H Jacobsson, Vibeke Strand, Philip J Mease, Jakob Kjellberg
OBJECTIVES: To comprehensively study the comorbidities, healthcare and public transfer (allowance) costs in patients with psoriatic arthritis (PsA) before and after diagnosis. METHODS: Nationwide cohort study, using data from Danish registries from January 1998 through December 2014. A total of 10 525 patients with PsA and 20 777 matched general population comparator (GPC) subjects were included. Societal costs, employment status and occurrence of comorbidities in patients with PsA both before and after diagnosis were compared with GPC subjects...
January 30, 2017: Annals of the Rheumatic Diseases
journal
journal
20039
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"